Reduced-Intensity Hematopoietic Cell Transplantation for Patients with Primary Myelofibrosis: A Cohort Analysis from the Center for International Blood and Marrow Transplant ResearchVikas Gupta, Wael Saber, Koen M. Van Besien et al.|Transplantation and Cellular Therapy|2013Cited by 148
Ibrutinib as Treatment for Patients With Relapsed/Refractory Follicular Lymphoma: Results From the Open-Label, Multicenter, Phase II DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Journal of Clinical Oncology|2018Cited by 103
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR OutcomesChristopher R. Flowers, Edmund K. Waller, Luciano J. Costa et al.|Transplantation and Cellular Therapy|2016Cited by 24
Ibrutinib As Treatment for Chemoimmunotherapy-Resistant Patients with Follicular Lymphoma: First Results from the Open-Label, Multicenter, Phase 2 DAWN StudyAjay K. Gopal, Gilles Salles, Stephen J. Schuster et al.|Blood|2016Cited by 9
Matched Pair Comparison of Busulfan/Cyclophosphamide/Etoposide (BuCyE) to Carmustine/Etoposide/Cytarabine/Melphalan (BEAM) Conditioning Regimen Prior to Autologous Hematopoietic Cell Transplantation (autoHCT) for LymphomaMarcelo C. Pasquini, Edmund K. Waller, Jennifer Le Rademacher et al.|Transplantation and Cellular Therapy|2014Cited by 5